Importantly, we measured higher percentage of effector circulating memory T cells (CD3+, CD8+, CD44+, CD62L-) and central memory T cells (CD3+, CD8+, CD44+, CD62L+) in the tumor draining lymph nodes of FLU-4T1+ICV mice following tumor re-challenge (Figure 5E). This evidence concerns the gene SELL and neoplasm.